RU2502799C2 - Способ перепрограммирования соматических клеток - Google Patents

Способ перепрограммирования соматических клеток Download PDF

Info

Publication number
RU2502799C2
RU2502799C2 RU2009140903/10A RU2009140903A RU2502799C2 RU 2502799 C2 RU2502799 C2 RU 2502799C2 RU 2009140903/10 A RU2009140903/10 A RU 2009140903/10A RU 2009140903 A RU2009140903 A RU 2009140903A RU 2502799 C2 RU2502799 C2 RU 2502799C2
Authority
RU
Russia
Prior art keywords
cell
cells
oct
exogenously
proteins
Prior art date
Application number
RU2009140903/10A
Other languages
English (en)
Other versions
RU2009140903A (ru
Inventor
Рудольф ДЖЭНИШ
Джейкоб ХАННА
Мариус ВЕРНИГ
Кристофер Дж. ЛЕНГНЕР
Александр МАЙССНЕР
Оливер Тобиас БРЭМБРИНК
Рут ФОРМАН
Original Assignee
Уайтхед Инститьют Фор Биомедикал Рисёч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уайтхед Инститьют Фор Биомедикал Рисёч filed Critical Уайтхед Инститьют Фор Биомедикал Рисёч
Publication of RU2009140903A publication Critical patent/RU2009140903A/ru
Application granted granted Critical
Publication of RU2502799C2 publication Critical patent/RU2502799C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0273—Cloned vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8775—Murine embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Virology (AREA)

Abstract

Изобретение относится к области биотехнологии. Предложена композиция, применяемая для клеточной терапии. Композиция содержит плюрипотентные клетки млекопитающего и фармацевтически приемлемый носитель. Также раскрыт способ генерации перепрограммированной соматической клетки. Предложенная группа изобретений может быть использована в области клеточной терапии. 3 н. и 21 з.п. ф-лы, 5 ил., 6 табл., 3 пр.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132

Claims (24)

1. Композиция, применяемая для клеточной терапии, содержащая выделенные плюрипотентные клетки млекопитающего и фармацевтически приемлемый носитель, отличающаяся тем, что выделенные плюрипотентные клетки млекопитающего
(а) экспрессируют эндогенные Oct4 и Nanog;
(б) будучи инъецированы SCID мышам, дифференцируются в клетки тканей, имеющих характеристики эндодермы, мезодермы и эктодермы;
(в) не экспрессируют селективный маркер, функционально связанный с эндогенным геном плюрипотентности, и
(г) являются перепрограммированными соматическими клетками млекопитающего.
2. Композиция по п.1, отличающаяся тем, что, по меньшей мере, 50% клеток резистентны к деметилированию ДНК.
3. Композиция по п.1, отличающаяся тем, что клетки выживают в условиях, в которых экспрессия ДНК-метилтрансферазы I снижается, по меньшей мере, на 50%.
4. Композиция по п.1, отличающаяся тем, что клетки не являются генетически модифицированными.
5. Композиция по п.1, отличающаяся тем, что клетки содержат, по меньшей мере, одну генную модификацию.
6. Композиция по п.1, отличающаяся тем, что клетки генетически соответствуют донору указанных соматических клеток или донору клетки-предшественника указанных соматических клеток, причем указанный донор является индивидуумом, нуждающимся в клеточной терапии.
7. Композиция по п.1, отличающаяся тем, что клеточная терапия включает введение выделенных плюрипотентных клеток млекопитающего индивидууму, нуждающемуся в клеточной терапии.
8. Композиция по п.7, отличающаяся тем, что выделенные плюрипотентные клетки млекопитающего предназначены для введения индивидууму для лечения повреждения или недостатка клеток в мышце, кости, хряще, гематопоэтической системе, мочевом пузыре, мозге, пищеводе, фаллопиевой трубе, сердце, кишечнике, желчном пузыре, почке, печени, легком, яичнике, поджелудочной железе, предстательной железе, позвоночнике, селезенке, желудке, яичке, вилочковой железе, щитовидной железе, трахее, мочеточнике, уретре, матке.
9. Способ генерации перепрограммированной соматической клетки, включающий стадии:
(а) введение в соматическую клетку одного или более экзогенных генов или белков, которые содействуют перепрограммированию указанной клетки в плюрипотентное состояние, причем один или более экзогенно введенных генов или белков включают Oct-4, Sox-2, c-Myc или Klf4 или их комбинацию, и причем указанная клетка перепрограммируется в плюрипотентное состояние, в котором клетка (i) резистентна к деметилированию ДНК; (ii) экспрессирует эндогенный Oct4; и (iii) будучи инъецирована SCID мышам, дифференцируется в клетки тканей, имеющих характеристики эндодермы, мезодермы и эктодермы.
10. Способ по п.9, отличающийся тем, что включает два или более введенных экзогенно генов или белков, выбранных из группы, состоящей из Oct-4, Nanog, Sox-2, c-Myc, Lin28 и Klf4.
11. Способ по п.10, отличающийся тем, что два или более введенных экзогенно генов или белков представляют собой Oct-4 и Nanog.
12. Способ по п.10, отличающийся тем, что два или более введенных экзогенно генов или белков представляют собой Oct-4 и Sox-2.
13. Способ по п.10, отличающийся тем, что два или более введенных экзогенно генов или белков представляют собой Oct-4 и Klf-4.
14. Способ по п.9, отличающийся тем, что экзогенные гены или белки Oct-4, Nanog, Sox-2, с-Мус и Klf4 вводят в клетку экзогенно.
15. Способ по п.9, отличающийся тем, что один или более введенных экзогенно генов вводят путем трансфекции.
16. Способ по п.9, отличающийся тем, что один или более введенных экзогенно генов вводят путем вирусного инфицирования.
17. Способ по п.9, дополнительно включающий функциональную инактивацию, по меньшей мере, одного из указанных введенных экзогенно генов.
18. Способ по п.17, отличающийся тем, что включает эксцизию, по меньшей мере, участка указанного введенного экзогенно гена с помощью введения в указанную клетку сайт-специфической рекомбиназы или экспрессии сайт-специфической рекомбиназы в клетке.
19. Способ перепрограммирования дифференцированной соматической клетки в плюрипотентное состояние, включающий стадии:
(а) контактирование дифференцированной соматической клетки, по меньшей мере, с одним перепрограммирующим агентом, который способствует перепрограммированию указанной клетки в плюрипотентное состояние, причем, по меньшей мере, один перепрограммирующий агент выбирают из группы, состоящей из Oct-4, Sox-2, Klf4, Nanog, Lin28 и с-Мус; и
(б) поддержание указанной клетки в условиях, подходящих для пролиферации указанной клетки и для активности указанного, по меньшей мере, одного перепрограммирующего агента в течение периода времени, достаточного для того, чтобы начать перепрограммирование указанной клетки.
20. Способ по п.19, отличающийся тем, что указанный, по меньшей мере, один перепрограммирующий агент представляет собой полинуклеотид.
21. Способ по п.19, отличающийся тем, что указанный, по меньшей мере, один перепрограммирующий агент представляет собой полипептид.
22. Способ по п.19, отличающийся тем, что дополнительно включает приведение дифференцированной соматической клетки в контакт с 5-азацитидином, трихостатином A (TSA) или вальпроевой кислотой.
23. Способ по п.19, отличающийся тем, что дифференцированная соматическая клетка представляет собой частично дифференцированную клетку.
24. Способ по п.19, отличающийся тем, что дифференцированная соматическая клетка представляет собой полностью дифференцированную клетку.
RU2009140903/10A 2007-04-07 2008-04-07 Способ перепрограммирования соматических клеток RU2502799C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US92212107P 2007-04-07 2007-04-07
US60/922,121 2007-04-07
US95934107P 2007-07-12 2007-07-12
US60/959,341 2007-07-12
US3606508P 2008-03-12 2008-03-12
US61/036,065 2008-03-12
PCT/US2008/004516 WO2008124133A1 (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells

Publications (2)

Publication Number Publication Date
RU2009140903A RU2009140903A (ru) 2011-05-20
RU2502799C2 true RU2502799C2 (ru) 2013-12-27

Family

ID=39831277

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009140903/10A RU2502799C2 (ru) 2007-04-07 2008-04-07 Способ перепрограммирования соматических клеток

Country Status (9)

Country Link
US (4) US9382515B2 (ru)
EP (3) EP2145000A4 (ru)
JP (8) JP2010523117A (ru)
CN (2) CN101932705A (ru)
AU (1) AU2008236629B2 (ru)
CA (2) CA2683056C (ru)
MX (2) MX348010B (ru)
RU (1) RU2502799C2 (ru)
WO (1) WO2008124133A1 (ru)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US8137907B2 (en) 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
US20070044164A1 (en) 2005-05-31 2007-02-22 Cold Spring Harbor Laboratory Methods for producing microRNAs
CA2617611A1 (en) 2005-08-01 2007-02-08 Nupotential, Llc Production of reprogrammed cells with restored potential
EP4223769A3 (en) 2005-12-13 2023-11-01 Kyoto University Nuclear reprogramming factor
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
CN101932705A (zh) 2007-04-07 2010-12-29 怀特黑德生物医学研究所 体细胞重编程
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
EP2198011B1 (en) 2007-08-31 2016-06-08 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
US20110190729A1 (en) * 2007-11-30 2011-08-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving sox2 protein
EP2224940A1 (en) * 2007-11-30 2010-09-08 Cytomatrix PTY LTD Methods of inducing pluripotency involving oct4 protein
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
KR101532442B1 (ko) * 2007-12-10 2015-06-29 고쿠리츠 다이가쿠 호진 교토 다이가쿠 효율적인 핵 초기화 방법
JP5626619B2 (ja) * 2008-12-08 2014-11-19 国立大学法人京都大学 効率的な核初期化方法
WO2009126655A2 (en) * 2008-04-07 2009-10-15 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through use of a small molecule modulator
SG10201400329YA (en) 2008-05-02 2014-05-29 Univ Kyoto Method of nuclear reprogramming
CA2969377C (en) 2008-06-13 2019-12-03 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
KR101642790B1 (ko) 2008-07-07 2016-07-27 다카라 바이오 가부시키가이샤 다능성 줄기세포의 제조방법
WO2010027062A1 (ja) * 2008-09-04 2010-03-11 独立行政法人理化学研究所 B細胞由来iPS細胞およびその用途
US20100062534A1 (en) * 2008-09-09 2010-03-11 The General Hospital Corporation Inducible lentiviral vectors for reprogramming somatic cells
WO2010056808A2 (en) * 2008-11-12 2010-05-20 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
WO2010075330A1 (en) 2008-12-23 2010-07-01 Segetis, Inc. Ketal amide compounds, methods of making, and applications
EP2607476B1 (en) * 2009-02-27 2015-04-08 Kyoto University Novel nuclear reprogramming substance
ES2900277T3 (es) * 2009-03-20 2022-03-16 Mesoblast Inc Producción de células pluripotentes reprogramadas
CN101580816B (zh) * 2009-04-23 2012-02-29 中国科学院广州生物医药与健康研究院 诱导多能性干细胞快速高效产生的新型无血清培养基以及使用其的方法
EP2421956A4 (en) * 2009-04-24 2013-10-02 Whitehead Biomedical Inst COMPOSITIONS AND METHODS FOR OBTAINING OR CULTURING PLURIPOTENTER CELLS
JP5886195B2 (ja) 2009-07-09 2016-03-16 ホワイトヘッド・インスティチュート・フォア・バイオメディカル・リサーチ 哺乳動物遺伝学のための組成物および方法、ならびにその使用
JP5709015B2 (ja) 2009-08-19 2015-04-30 国立大学法人大阪大学 角膜移植用シート
US8420352B2 (en) 2009-08-27 2013-04-16 Synaptic Research, Llc Protein delivery system to generate pluripotent stem (iPS) cells or tissue specific cells
AU2010312291A1 (en) 2009-10-29 2012-06-21 Mcmaster University Generating induced pluripotent stem cells and progenitor cells from fibroblasts
US9696297B2 (en) * 2009-12-23 2017-07-04 Salk Institute For Biological Studies Method for preparing an X chromosome inactivated female human neural cell
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9089520B2 (en) * 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
CA2806858C (en) 2010-08-04 2021-06-15 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
US20130296183A1 (en) 2010-09-17 2013-11-07 President And Fellows Of Harvard College Functional genomics assay for characterizing pluripotent stem cell utility and safety
JP5888753B2 (ja) 2010-11-04 2016-03-22 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
JP6029137B2 (ja) 2010-12-03 2016-11-24 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
JP6273842B2 (ja) * 2011-02-25 2018-02-07 学校法人慶應義塾 ｉＰＳ細胞クローンの選択方法、及びその選択方法に用いる遺伝子の選択方法
CN102731653B (zh) * 2011-04-06 2013-12-11 李凌松 一种抗磷酸化Oct4蛋白的抗体及其应用
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
KR20240039237A (ko) 2011-12-05 2024-03-26 팩터 바이오사이언스 인크. 세포를 형질감염시키는 방법들 및 생성물들
US20130202649A1 (en) * 2012-01-17 2013-08-08 The Board Of Trustees Of The Leland Stanford Junior University Activation of innate immunity for nuclear reprogramming of somatic cells
KR20200084916A (ko) * 2012-04-24 2020-07-13 브이셀 세라퓨틱스 인코포레이티드 다능성 세포를 다시 생성하는 방법
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
JP6433896B2 (ja) 2012-08-13 2018-12-05 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 組織再生のためのエキソソームおよびマイクロリボ核酸
US20150267174A1 (en) 2012-10-09 2015-09-24 Nakanobu Hayashi Reprogramming peptide and use thereof
US20140287932A1 (en) 2012-10-25 2014-09-25 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
KR20230154283A (ko) 2012-11-01 2023-11-07 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
EP2948776B8 (en) 2013-01-25 2020-02-26 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CN108464278B (zh) * 2013-03-11 2021-05-04 瑞泽恩制药公司 表达嵌合的主要组织相容性复合物(mhc)ii类分子的转基因小鼠
EP2971056A4 (en) 2013-03-15 2016-11-23 Whitehead Biomedical Inst CELLULAR DISCOVERY PLATFORM FOR NEURODEGENERATIVE DISEASES
ES2831424T3 (es) 2013-04-23 2021-06-08 Yeda Res & Dev Células madre pluripotentes naif aisladas y métodos para generarlas
ES2791598T3 (es) 2013-06-05 2020-11-05 Bellicum Pharmaceuticals Inc Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa
WO2014200905A2 (en) 2013-06-10 2014-12-18 President And Fellows Of Harvard College Early developmental genomic assay for characterizing pluripotent stem cell utility and safety
EP3045531B1 (en) 2013-09-12 2023-08-30 Kaneka Corporation Method for inducing differentiation of induced pluripotent stem cells and method for selecting induced pluripotent stem cells
WO2015069736A1 (en) 2013-11-08 2015-05-14 The Mclean Hospital Corporation METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS
EP4249036A3 (en) 2014-01-31 2023-10-25 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
EP3991751A1 (en) 2014-02-10 2022-05-04 The Board of Trustees of the Leland Stanford Junior University Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mrna
CN106459897A (zh) 2014-03-19 2017-02-22 V 细胞治疗公司 与多能细胞有关的方法
EP3194572B1 (en) 2014-07-30 2023-10-25 Yeda Research and Development Co. Ltd. Media for culturing pluripotent stem cells
EP3191578B1 (en) 2014-09-12 2020-11-04 Whitehead Institute for Biomedical Research Cells expressing apolipoprotein e and uses thereof
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
JP2018504122A (ja) 2015-01-26 2018-02-15 フェイト セラピューティクス，インコーポレイテッド 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP7199809B2 (ja) 2015-02-13 2023-01-06 ファクター バイオサイエンス インコーポレイテッド 核酸製品及びその投与方法
EP3283502A4 (en) * 2015-04-07 2019-04-03 The General Hospital Corporation METHODS FOR REACTIVATION OF GENES ON INACTIVE X CHROMOSOME
EP3708680B8 (en) 2015-04-15 2023-08-30 University of Massachusetts Compositions and methods for xi chromosome reactivation
US20170044609A1 (en) * 2015-04-24 2017-02-16 California Institute Of Technology Reactivation of x chromosome genes
WO2016172734A1 (en) 2015-04-24 2016-10-27 California Institute Of Technology Reactivation of x chromosome genes
CN108135935A (zh) 2015-07-21 2018-06-08 儿童医疗中心有限公司 表达pd-l1的造血干细胞及其用途
US10662409B2 (en) * 2015-09-09 2020-05-26 Trustees Of Tufts College Methods of generating neural stem cells
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
CN105624117A (zh) * 2016-01-18 2016-06-01 哈尔滨医科大学 一种低氧促进小鼠成纤维细胞重编程为心肌细胞的方法
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
WO2017223199A1 (en) * 2016-06-22 2017-12-28 Xcell Biosciences, Inc. Methods for increasing cell culture transfection efficiency and cellular reprogramming
IL264439B2 (en) 2016-08-17 2024-08-01 Factor Bioscience Inc A suitable viral preparation containing a synthetic messenger RNA encoding a gene editing protein for use in cancer treatment and a synthetic messenger RNA encoding a gene editing protein for use in therapy
EP3500675A4 (en) 2016-08-19 2020-01-29 Whitehead Institute for Biomedical Research METHOD FOR EDITING DNA METHYLATION
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
CN106544315A (zh) * 2016-10-12 2017-03-29 广东艾时代生物科技有限责任公司 一种脂肪间充质干细胞诱导成多能干细胞的方法
EP3532044A4 (en) 2016-10-27 2020-07-29 California Institute of Technology HDAC-INHIBITING COMPOSITIONS FOR REACTIVATING THE X-CHROMOSOME
EP3565891B1 (en) 2017-01-09 2023-04-12 Whitehead Institute for Biomedical Research Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
JPWO2018159805A1 (ja) 2017-03-03 2020-01-09 国立大学法人京都大学 膵前駆細胞の製造方法
CA3040626A1 (en) * 2017-04-05 2018-10-11 Centro De Neurociencias E Biologia Celular Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US20200208093A1 (en) 2017-06-14 2020-07-02 Takeda Pharmaceutical Company Limited Cell-sealing device
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
PL241125B1 (pl) 2017-11-30 2022-08-08 Gdanski Univ Medyczny Kompozycja farmaceutyczna do zastosowania jako środek do pobudzania regeneracji lub gojenia ran
MX2020005668A (es) 2017-11-30 2020-11-24 Univ Kyoto Metodo de cultivo de celulas.
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
CN111868224A (zh) 2017-12-22 2020-10-30 国立大学法人京都大学 细胞培养装置，培养液抽吸器及细胞培养方法
CN108624621B (zh) * 2018-01-17 2019-04-12 中国科学院上海生命科学研究院 非人灵长类的体细胞克隆动物的制备方法
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
US20210060210A1 (en) 2018-03-19 2021-03-04 Kyoto University Hydrogel capsule
US12018281B2 (en) 2018-03-30 2024-06-25 Kyoto University Cardiomyocyte maturation promoter
MX2020010184A (es) 2018-03-30 2020-10-28 Orizuru Therapeutics Inc Compuesto heterociclico.
WO2019189545A1 (ja) 2018-03-30 2019-10-03 国立大学法人京都大学 細胞の製造方法
AU2019261083A1 (en) 2018-04-23 2020-11-12 Orizuru Therapeutics, Inc. Growth inhibitor
US20210292708A1 (en) 2018-08-03 2021-09-23 Kyoto University Cell production method
JP7436990B2 (ja) 2018-08-10 2024-02-22 国立大学法人京都大学 カチオン性脂質を用いた心筋細胞へのトランスフェクション方法
SG11202100829SA (en) 2018-08-10 2021-03-30 Univ Kyoto Method for producing cd3-positive cell
TW202024322A (zh) 2018-08-22 2020-07-01 國立大學法人京都大學 腸管神經前驅細胞的製造方法
MX2021002373A (es) 2018-08-31 2021-07-15 Noile Immune Biotech Inc Celulas t que expresan car y vector de expresion de car.
SG11202102748WA (en) 2018-09-19 2021-04-29 Takeda Pharmaceuticals Co Insulin-producing cells
US20210308215A1 (en) 2018-09-21 2021-10-07 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching mrna coding for secreted proteins
WO2020080270A1 (ja) 2018-10-15 2020-04-23 公立大学法人横浜市立大学 栄養組成物
TW202039543A (zh) 2018-12-27 2020-11-01 國立大學法人京都大學 Ｔ細胞受體的變體
WO2020150391A1 (en) * 2019-01-15 2020-07-23 Falcon Therapeutics, Inc. Engineered stem cell constructs and uses thereof
JP7508045B2 (ja) 2019-02-01 2024-07-01 国立大学法人京都大学 細胞の検出方法
US20220252575A1 (en) 2019-03-29 2022-08-11 Public University Corporation Yokohama City University Screening method and toxicity evaluation method
KR20210151903A (ko) 2019-04-10 2021-12-14 오리즈루 세라퓨틱스 가부시키가이샤 생체 조직형 구조체의 제조 방법
JP7541700B2 (ja) 2019-06-11 2024-08-29 国立大学法人京都大学 腎間質細胞の製造方法
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
CA3151819A1 (en) 2019-08-20 2021-02-25 Orizuru Therapeutics, Inc. Method for enriching cardiac myocytes
AU2020371382A1 (en) 2019-10-21 2022-04-14 Orizuru Therapeutics, Inc. Proliferation inhibitor
CN114729318A (zh) 2019-11-01 2022-07-08 国立大学法人京都大学 T细胞的制备方法
TW202134429A (zh) 2019-11-25 2021-09-16 國立大學法人京都大學 Ｔ細胞主細胞庫
EP4123016A4 (en) 2020-03-19 2024-06-19 Orizuru Therapeutics, Inc. METHOD FOR THE PURIFICATION OF CARDIOMYOCYTES
CN115885035A (zh) 2020-03-19 2023-03-31 千纸鹤治疗公司 心肌细胞的精制方法
TW202204609A (zh) 2020-03-31 2022-02-01 國立大學法人京都大學 Ｔ前驅細胞的製造方法
JPWO2021241668A1 (ru) 2020-05-28 2021-12-02
CN112201307A (zh) * 2020-09-23 2021-01-08 温州医科大学 一种转录本注释方法以及筛选长非编码rna和内源逆转录病毒来源长非编码rna的方法
JPWO2022107877A1 (ru) 2020-11-20 2022-05-27
EP4293105A1 (en) 2021-02-09 2023-12-20 Orizuru Therapeutics, Inc. Maturation agent
CN116964193A (zh) 2021-03-09 2023-10-27 国立大学法人东京医科齿科大学 细胞簇的制造方法
EP4321534A1 (en) 2021-04-08 2024-02-14 Takeda Pharmaceutical Company Limited Method for activating t-cells
CN113424794B (zh) * 2021-04-16 2022-07-26 安徽农业大学 一种优质抗病型地方鸡新品系选育方法
WO2022230919A1 (ja) 2021-04-28 2022-11-03 国立大学法人 東京医科歯科大学 細胞の製造方法
CN113278686A (zh) * 2021-06-11 2021-08-20 扬州大学 一种研究dna甲基化调控重编程过程的方法
MX2024003619A (es) 2021-09-27 2024-04-19 Univ Kyoto Metodo para producir celulas t.
WO2024050517A1 (en) * 2022-09-02 2024-03-07 The University Of North Carolina At Chapel Hill Methods of making and using anticancer reprogrammed b cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2249039C2 (ru) * 1999-02-04 2005-03-27 Текнион Рисерч Энд Дивелопмент Фаундейшн Лтд. Способ размножения/поддержания недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты), способ приготовления кондиционированной среды стромальных клеток, способ трансплантации недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты)
US20070032447A1 (en) * 2005-08-01 2007-02-08 Eilertsen Kenneth J Production of reprogrammed cells with restored potential

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
US4846835A (en) 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
WO1995003402A1 (en) 1993-07-22 1995-02-02 Merck & Co., Inc. EXPRESSION OF HUMAN INTERLEUKIN-1β IN A TRANSGENIC ANIMAL
US5723331A (en) 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5698446A (en) 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9809178D0 (en) 1998-04-29 1998-07-01 Univ Edinburgh Nuclear reprogramming of somatic cells
WO2000027995A1 (en) 1998-11-09 2000-05-18 Monash University Embryonic stem cells
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
AU2002242173A1 (en) 2001-02-15 2002-08-28 Whithead Institute For Biomedical Research Stem cell identification
US20020137460A1 (en) * 2001-03-08 2002-09-26 Howard Sun Universal multi-band (5 bands and more) keyless RF remote control unit using bluetooth radio module as the base
AU2002306374B2 (en) 2001-05-31 2008-01-24 Dainippon Sumitomo Pharma Co., Ltd. Genes with ES cell-specific expression
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
CA2461185A1 (en) 2001-09-21 2003-04-03 Japan Science And Technology Corporation Method of screening reprogramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs
DE10162080A1 (de) 2001-12-10 2003-06-26 Albrecht Mueller Verfahren zur Herstellung von Stammzellen mit erhöhtem Entwicklungspotential
GB0202149D0 (en) 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
GB0211904D0 (en) 2002-05-23 2002-07-03 Medical Res Council Nuclear transfer
EP1546346A4 (en) 2002-07-23 2006-02-08 Nanodiagnostics Inc MARKERS OF EMBRYONIC STEM CELLS, AND USE THEREOF
AU2004252568B2 (en) * 2003-06-27 2011-06-30 Ethicon, Incorporated Regeneration and repair of neural tissue using postpartum-derived cells
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
WO2005080598A1 (ja) 2004-02-19 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 体細胞核初期化物質のスクリーニング方法
EP1574499A1 (en) 2004-03-08 2005-09-14 DKFZ Deutsches Krebsforschungszentrum Inhibitors of DNA methylation in tumor cells
BRPI0509179A (pt) 2004-03-23 2007-09-18 Daiichi Asubio Pharma Co Ltd método de crescimento de célula tronco pluripotente
WO2006050257A2 (en) 2004-10-29 2006-05-11 Massachusetts Institute Of Tecchnology Detection of ion channel or receptor activity
JP2008538898A (ja) * 2005-04-29 2008-11-13 イノベイティブ デイリー プロダクツ ピーティーワイ リミティッド アズ トラスティー フォー ザ パーティシパンツ オブ ザ コーペラティブ リサーチ センター フォー イノベイティブ デイリー プ 哺乳動物胚から幹細胞または幹細胞様細胞を作製するための方法
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
EP4223769A3 (en) 2005-12-13 2023-11-01 Kyoto University Nuclear reprogramming factor
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
EP2038247A4 (en) 2006-06-27 2011-08-17 Jncasr Bangalore SPECIFIC SITE INHIBITORS OF HISTONE METHYLTRANSFERASE [HMTASE] AND PROCESS FOR PREPARING SAME
EP2137296A2 (en) * 2007-03-23 2009-12-30 Wisconsin Alumni Research Foundation Somatic cell reprogramming
CN101932705A (zh) 2007-04-07 2010-12-29 怀特黑德生物医学研究所 体细胞重编程
US20120282229A1 (en) * 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
EP2198011B1 (en) 2007-08-31 2016-06-08 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
WO2009061442A1 (en) 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
CN104694570B (zh) 2008-03-17 2019-07-16 斯克里普斯研究所 用于产生诱导的多能干细胞的组合化学遗传方法
US20110061118A1 (en) 2008-03-17 2011-03-10 Helmholtz Zentrum Munchen Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
SG10201400329YA (en) 2008-05-02 2014-05-29 Univ Kyoto Method of nuclear reprogramming
CA2969377C (en) 2008-06-13 2019-12-03 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
WO2010033920A2 (en) 2008-09-19 2010-03-25 Whitehead Institute For Biomedical Research Compositions and methods for enhancing cell reprogramming
US20100150889A1 (en) 2008-12-17 2010-06-17 The Uab Research Foundation Polycistronic Vector For Human Induced Pluripotent Stem Cell Production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2249039C2 (ru) * 1999-02-04 2005-03-27 Текнион Рисерч Энд Дивелопмент Фаундейшн Лтд. Способ размножения/поддержания недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты), способ приготовления кондиционированной среды стромальных клеток, способ трансплантации недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты)
US20070032447A1 (en) * 2005-08-01 2007-02-08 Eilertsen Kenneth J Production of reprogrammed cells with restored potential

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SAVARESE ЕТ AL.: 'Hematopoietic Precursor Cells Transiently Reestablish Permissiveness for X inactivation' MOLECULAR AND CELLULAR BIOLOGY vol. 26, no. 19, October 2006, pages 7167-7177. *
TAKAHASHI K. ЕТ AL.: 'Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors' CELL vol. 126, no. 4, 25 August 2006, pages 663-676. *
TAKAHASHI K. ЕТ AL.: 'Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors' CELL vol. 126, no. 4, 25 August 2006, pages 663-676. SAVARESE ЕТ AL.: 'Hematopoietic Precursor Cells Transiently Reestablish Permissiveness for X inactivation' MOLECULAR AND CELLULAR BIOLOGY vol. 26, no. 19, October 2006, pages 7167-7177. *

Also Published As

Publication number Publication date
EP2145000A4 (en) 2010-05-05
AU2008236629A1 (en) 2008-10-16
RU2009140903A (ru) 2011-05-20
JP2024024049A (ja) 2024-02-21
US9714414B2 (en) 2017-07-25
JP2020014480A (ja) 2020-01-30
CN101932705A (zh) 2010-12-29
US20150118755A1 (en) 2015-04-30
WO2008124133A1 (en) 2008-10-16
US20170342386A1 (en) 2017-11-30
CN105861443A (zh) 2016-08-17
JP2018086017A (ja) 2018-06-07
US20110076678A1 (en) 2011-03-31
EP3878949A1 (en) 2021-09-15
JP2022031941A (ja) 2022-02-22
CA2683056A1 (en) 2008-10-16
MX2009010847A (es) 2010-04-27
AU2008236629B2 (en) 2014-03-06
JP6934501B2 (ja) 2021-09-15
US9382515B2 (en) 2016-07-05
JP2015051022A (ja) 2015-03-19
CA3071055A1 (en) 2008-10-16
US10093904B2 (en) 2018-10-09
EP2145000A1 (en) 2010-01-20
MX348010B (es) 2017-05-23
JP2017035113A (ja) 2017-02-16
EP2626416A2 (en) 2013-08-14
CA2683056C (en) 2020-03-24
EP2626416A3 (en) 2013-12-18
US20190241874A1 (en) 2019-08-08
MX352541B (es) 2017-11-29
JP2010523117A (ja) 2010-07-15
JP2020014479A (ja) 2020-01-30

Similar Documents

Publication Publication Date Title
RU2502799C2 (ru) Способ перепрограммирования соматических клеток
JP2017035113A5 (ru)
Patel et al. Advances in reprogramming somatic cells to induced pluripotent stem cells
Cheng et al. Protecting against wayward human induced pluripotent stem cells with a suicide gene
ES2900277T3 (es) Producción de células pluripotentes reprogramadas
Kramer et al. Systematic review of induced pluripotent stem cell technology as a potential clinical therapy for spinal cord injury
Abou-Saleh et al. The march of pluripotent stem cells in cardiovascular regenerative medicine
Stocum et al. Stretching the limits: stem cells in regeneration science
Anastasia et al. Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine
US20210238604A1 (en) Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases
Han et al. Induced pluripotent stem cells: emerging techniques for nuclear reprogramming
WO2012079278A1 (zh) 诱导性多能干细胞的制备方法以及用于制备诱导性多能干细胞的培养基
Mao et al. Reprogramming stem cells in regenerative medicine
Hybiak et al. Reprogramming and transdifferentiation-two key processes for regenerative medicine
WO2019213505A1 (en) Enhancement of fibroblast plasticity for treatment of disc degeneration
WO2013004135A1 (zh) 诱导性多能干细胞的制备方法和用于制备诱导性多能干细胞的培养基
Rajasingh Reprogramming of somatic cells
Guillot Induced pluripotent stem (iPS) cells from human fetal stem cells
Cherkashova et al. Methods of generation of induced pluripotent stem cells and their application for the therapy of central nervous system diseases
Li et al. A promising approach to iPSC-based cell therapy for diabetic wound treatment: direct lineage reprogramming
Panda et al. Non-viral reprogramming and induced pluripotent stem cells for cardiovascular therapy
Ramesh et al. Somatic cell dedifferentiation/reprogramming for regenerative medicine
Kuzma-Hunt et al. Opening the “Black Box” Underlying Barriers to the Use of Canine Induced Pluripotent Stem Cells: A Narrative Review
Kang et al. Adipose stromal cells are a more efficient source than adipose stem cells in retrovirus-mediated iPS induction
Heng et al. Induced adult stem (iAS) cells and induced transit amplifying progenitor (iTAP) cells—a possible alternative to induced pluripotent stem (iPS) cells?